<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879863</url>
  </required_header>
  <id_info>
    <org_study_id>ADX-102-DED-012</org_study_id>
    <nct_id>NCT03879863</nct_id>
  </id_info>
  <brief_title>The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease</brief_title>
  <official_title>The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RENEW Trial is a Multi-Center, Randomized, Double-Masked, Parallel-Group,&#xD;
      Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of&#xD;
      Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Actual">October 4, 2019</completion_date>
  <primary_completion_date type="Actual">October 4, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject-reported ocular dryness score (0 - 100 VAS)</measure>
    <time_frame>Efficacy assessment period (Week 2 through Week 12)</time_frame>
    <description>The method of assessment is subject-reported ocular dryness score (0 - 100 VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluorescein nasal region score (Ora Calibra® scale)</measure>
    <time_frame>Efficacy assessment period (Week 2 through Week 12)</time_frame>
    <description>The method of assessment is Fluorescein nasal region score (Ora Calibra® scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluorescein staining</measure>
    <time_frame>Efficacy assessment period (Week 2 through Week 12)</time_frame>
    <description>The method of assessment for this outcome is the Fluorescein staining Ora Calibra®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unanesthetized Schirmer's Test</measure>
    <time_frame>Efficacy assessment period (Week 2 through Week 12)</time_frame>
    <description>The method of assessment for this outcome is the Schirmer test strip.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">406</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%) QID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Ophthalmic Solution QID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%) QID to BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Ophthalmic Solution QID to BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reproxalap Ophthalmic Solution (0.25%) QID</intervention_name>
    <description>Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks</description>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%) QID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Ophthalmic Solution QID</intervention_name>
    <description>Vehicle Ophthalmic Solution administered QID for twelve weeks</description>
    <arm_group_label>Vehicle Ophthalmic Solution QID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reproxalap Ophthalmic Solution (0.25%) QID to BID</intervention_name>
    <description>Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks</description>
    <arm_group_label>Reproxalap Ophthalmic Solution (0.25%) QID to BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Ophthalmic Solution QID to BID</intervention_name>
    <description>Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks</description>
    <arm_group_label>Vehicle Ophthalmic Solution QID to BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be at least 18 years of age of either gender and any race;&#xD;
&#xD;
          -  Have a reported history of dry eye for at least 6 months prior to Visit 1;&#xD;
&#xD;
          -  Have a history of use or desire to use eye drops for dry eye symptoms within 6 months&#xD;
             of Visit 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have any clinically significant slit-lamp findings at Visit 1, including active&#xD;
             blepharitis; meibomian gland dysfunction (MGD); lid margin inflammation; or active&#xD;
             ocular allergies that require therapeutic treatment, or, in the opinion of the&#xD;
             investigator may interfere with the assessment of the safety or efficacy of reproxalap&#xD;
             or vehicle;&#xD;
&#xD;
          -  Have or be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal) or&#xD;
             active ocular inflammation at Visit 1;&#xD;
&#xD;
          -  Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses&#xD;
             during the study;&#xD;
&#xD;
          -  Have used any eye drops within 2 hours of Visit 1;&#xD;
&#xD;
          -  Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the&#xD;
             last 12 months;&#xD;
&#xD;
          -  Have used ophthalmic cyclosporine or lifitigrast 5.0% ophthalmic solution within 90&#xD;
             days of Visit 1;&#xD;
&#xD;
          -  Have any planned ocular and/or lid surgeries over the study period or any ocular&#xD;
             surgery within 6 months of Visit 1;&#xD;
&#xD;
          -  Have used temporary or permanent punctal plugs within 30 days prior to Visit 1 or&#xD;
             anticipate their use during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <disposition_first_submitted>December 2, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>December 2, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 7, 2020</disposition_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

